BioCentury | Jun 8, 2015
Finance

Xanthopoulos' passion play

...at Enterprise Partners Venture Capital for about a year between CEO roles at Regulus and Anadys Pharmaceuticals Inc....
BioCentury | Oct 20, 2014
Product Development

Walking the toll road

...Coley Pharmaceutical Group by Pfizer Inc. for $230 million. Then in 2006, Novartis AG and Anadys Pharmaceuticals Inc....
...was apparently the dosing schedule. On a conference call in 2007 to discuss the discontinuation, Anadys...
...dosing schedule could improve both efficacy and tolerability. In an interview for this article, former Anadys...
BioCentury | Jun 16, 2014
Company News

Celladon management update

...a newly created position, formerly SVP of legal affairs, general counsel and corporate secretary at Anadys Pharmaceuticals Inc....
BioCentury | May 27, 2013
Finance

Targeting translation

...Effector will focus on cancer and seek partners for other indications. Worland was CEO of Anadys Pharmaceuticals Inc....
...Lilly Biotech Center in San Diego; and Kevin Eastwood, formerly SVP of corporate development at Anadys...
BioCentury | Oct 22, 2012
Product Development

Nuclear pacifism

...recent attempts to bolster HCV pipelines with non-nucs include Roche 's acquisition last year of Anadys Pharmaceuticals Inc....
BioCentury | Aug 6, 2012
Strategy

Freedom to deal Strategy

...and up to $1.5 billion in milestones. In October 2011, Roche announced it would acquire Anadys Pharmaceuticals Inc....
BioCentury | Jul 16, 2012
Strategy

Burying Nutley

...development of some in-licensed molecules, including setrobuvir, a non-nucleoside NS5B inhibitor acquired when Roche purchased Anadys Pharmaceuticals Inc....
BioCentury | Jul 2, 2012
Strategy

Revving the engine

...at Harvard Medical School . Scientific co-founder of Exelixis Inc. (NASDAQ:EXEL); Cellzome AG ; and Anadys Pharmaceuticals Inc....
BioCentury | May 14, 2012
Company News

Ruga management update

...as CMO and head of clinical development, formerly SVP of drug development and CMO at Anadys Pharmaceuticals Inc....
BioCentury | Mar 5, 2012
Product Development

Dynamic duo

...in the HCV space, although they have yet to bear fruit. These included deals with Anadys Pharmaceuticals Inc....
...now part of GlaxoSmithKline plc ) and Intercell AG . In mid-2005, Novartis partnered with Anadys...
Items per page:
1 - 10 of 333
BioCentury | Jun 8, 2015
Finance

Xanthopoulos' passion play

...at Enterprise Partners Venture Capital for about a year between CEO roles at Regulus and Anadys Pharmaceuticals Inc....
BioCentury | Oct 20, 2014
Product Development

Walking the toll road

...Coley Pharmaceutical Group by Pfizer Inc. for $230 million. Then in 2006, Novartis AG and Anadys Pharmaceuticals Inc....
...was apparently the dosing schedule. On a conference call in 2007 to discuss the discontinuation, Anadys...
...dosing schedule could improve both efficacy and tolerability. In an interview for this article, former Anadys...
BioCentury | Jun 16, 2014
Company News

Celladon management update

...a newly created position, formerly SVP of legal affairs, general counsel and corporate secretary at Anadys Pharmaceuticals Inc....
BioCentury | May 27, 2013
Finance

Targeting translation

...Effector will focus on cancer and seek partners for other indications. Worland was CEO of Anadys Pharmaceuticals Inc....
...Lilly Biotech Center in San Diego; and Kevin Eastwood, formerly SVP of corporate development at Anadys...
BioCentury | Oct 22, 2012
Product Development

Nuclear pacifism

...recent attempts to bolster HCV pipelines with non-nucs include Roche 's acquisition last year of Anadys Pharmaceuticals Inc....
BioCentury | Aug 6, 2012
Strategy

Freedom to deal Strategy

...and up to $1.5 billion in milestones. In October 2011, Roche announced it would acquire Anadys Pharmaceuticals Inc....
BioCentury | Jul 16, 2012
Strategy

Burying Nutley

...development of some in-licensed molecules, including setrobuvir, a non-nucleoside NS5B inhibitor acquired when Roche purchased Anadys Pharmaceuticals Inc....
BioCentury | Jul 2, 2012
Strategy

Revving the engine

...at Harvard Medical School . Scientific co-founder of Exelixis Inc. (NASDAQ:EXEL); Cellzome AG ; and Anadys Pharmaceuticals Inc....
BioCentury | May 14, 2012
Company News

Ruga management update

...as CMO and head of clinical development, formerly SVP of drug development and CMO at Anadys Pharmaceuticals Inc....
BioCentury | Mar 5, 2012
Product Development

Dynamic duo

...in the HCV space, although they have yet to bear fruit. These included deals with Anadys Pharmaceuticals Inc....
...now part of GlaxoSmithKline plc ) and Intercell AG . In mid-2005, Novartis partnered with Anadys...
Items per page:
1 - 10 of 333